NEW YORK (GenomeWeb) — Luxembourg-based diagnostics firm Advanced Biological Laboratories announced today a collaboration with Mayo Clinic Laboratories to develop a clinical test to detect mutations associated with antiviral resistance in human cytomegalovirus.
The test will leverage next-generation sequencing to sequence PCR amplicons of the UL54 and UL97 genes in which drug resistance with CMV has been associated. ABL's software, DeepChek-CMV, will be used to analyze the data and to interpret possible drug resistance in the virus.
ABL noted that Mayo Clinic will have a financial interest in the new technology and added that any revenues the clinic receives will be used to support its not-for-profit mission in patient care, education, and research. Additional details about the deal were not disclosed.